Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Clinical research trials and Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer. Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "I" Clinical Trials Conditions > Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer



Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

For Condition: stage 4 renal cell cancer,recurrent renal cell cancer
Status: No longer recruiting
Sponsor(s): Blumenthal Cancer Center at Carolinas Medical Center ,
Synopsis: RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.
Details: OBJECTIVES: - Evaluate the response and disease-free survival of patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 and interferon alfa. - Assess the toxicity of this regimen. OUTLINE: Patients undergo nephrectomy if the diseased kidney makes up the bulk of the tumor burden. All patients receive subcutaneous interferon alfa on day 1 and interleukin-2 on days 3-5 of week 1, followed by reduced doses of interferon alfa and interleukin-2 on days 1, 3, and 5 of weeks 2-6. Patients are assessed for response approximately 2 months after initiating therapy. Patients with stable or responding disease undergo a second course; those who continue to respond may receive additional therapy provided toxicity is limited. Patients are followed for survival. PROJECTED ACCRUAL: 14 patients will be entered.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically proven renal cell cancer that is metastatic - No greater than 50% estimated hepatic replacement by tumor on CT or MRI - No symptomatic involvement of the CNS or a major nerve - Measurable disease required - Ineligible for treatment with low-dose interleukin-2 on another CMC protocol PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 50%-100% Life expectancy: - More than 3 months Hematopoietic: - No coagulopathy (i.e., platelet count less than 80,000/mm3) Hepatic: - AST and ALT no greater than 5 times normal Renal: - Creatinine less than 4.0 mg/dL Cardiovascular: - No symptomatic angina - No untreated coronary artery disease - No refractory arrhythmia - No abnormal left ventricular function Pulmonary: - No dyspnea on minimal exertion Other: - No site of ongoing bleeding - No systemic infection - No HIV antibody - No HBsAg - No requirement for steroids - No psychiatric disease that precludes informed consent or protocol treatment - No second malignancy except: - Basal cell skin carcinoma - Carcinoma in situ of the cervix - Not pregnant or nursing - Effective contraception required of fertile women PRIOR CONCURRENT THERAPY: Biologic therapy - No prior interleukin-2 Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - At least 28 days since prior treatment for renal cell cancer
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
RichardWhite,  Study Chair,  Blumenthal Cancer Center at Carolinas Medical Center

Blumenthal Cancer Center at Carolinas Medical Center
Charlotte,  North Carolina,  28232-2861
United States
 


Additional Information:
Study ID Numbers:  CDR0000065086;  CMC-09-95-14B,NCI-V96-1039
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002847

Other Recurrent Renal Cell Cancer Studies:
1. Interferon alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer

2. Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

3. PS-341 in Treating Patients With Metastatic Kidney Cancer

4. Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer

5. PEG-Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer

Related Studies:

Other recurrent renal cell cancer Clinical Trials
Other North Carolina Clinical Trials
Other Charlotte Clinical Trials

Interferon alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Modify your Search

  Other recurrent renal cell cancer Clinical Trials
  Other North Carolina Clinical Trials
  Other Charlotte Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103